Ashley Vermillion, N.P.; Decision and Order
DEA issued a Decision and Order against Ashley Vermillion, N.P., revoking her DEA registration based on findings of improper prescribing and failure to comply with controlled substance regulations.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Ashley Vermillion, N.P., and potentially other nurse practitioners or prescribers with similar DEA registration issues. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified; the order is effective immediately upon issuance.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA revoked Ashley Vermillion's registration to prescribe controlled substances due to violations of the Controlled Substances Act.
Who it affects
Ashley Vermillion, N.P., and potentially other nurse practitioners or prescribers with similar DEA registration issues.
What you must do
Review the specific violations cited in the order to ensure compliance; if you are a similar practitioner, audit your prescribing practices and PDMP usage.
Deadline
Not specified; the order is effective immediately upon issuance.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- New Maine law increases access to birth control at pharmacies - WGME
- Andrew Jonathan Morgan: Final Debarment Order
- SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
- Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments
- Schedules of Controlled Substances: Rescheduling of Marijuana; Withdrawal